Linda M. Rubinstein - 02 Aug 2024 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ John Rakow, Attorney-in-Fact
Issuer symbol: ADVM
Transactions as of: 02 Aug 2024
Net transactions value: $0
Form type: 4
Filing time: 06 Aug 2024, 16:10:05 UTC
Previous filing: 14 Feb 2024
Next filing: 27 Feb 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADVM	Stock Option (Right to Buy)	Award	$0	+62,083		$0.000000	62,083	02 Aug 2024	Common Stock	62,083	$7.15	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/3 of the total number of shares subject to the Option shall vest and become exercisable on the first anniversary of August 2, 2024 (the "Vesting Commencement Date"), and 1/36 of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, such that all of the shares shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Content

1/3 of the total number of shares subject to the Option shall vest and become exercisable on the first anniversary of August 2, 2024 (the "Vesting Commencement Date"), and 1/36 of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, such that all of the shares shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.